Kornimate/medical-research-clean huggingface dataset:
an exploratory study of ctdna-mrd in predicting the efficacy of esophageal squamous cell carcinoma

Conditions: Squamous Cell Carcinoma of Esophagus

Summary: the purpose of this study is to observe and evaluate the correlation between ctdna-mrd and the therapeutic effect and prognosis of stage ii-iva operable esophageal squamous cell carcinoma.

escc patients with ii-iva resection will undergo mrd examination at the following time: the first examination is before the operation, the second examination is 7-10 days after the operation, and then 1 month after the operation, 2 weeks after the end of adjuvant treatment (if available), the follow-up period (every 3 months if there is no postoperative treatment) and the progress (the progress of the disease confirmed by the researcher), the patients will receive close mrd monitoring to evaluate the correlation between ctdna-mrd and therapeutic efficacy and prognosis.

Eligibility criteria:
inclusion criteria: 1. patients with stage ii-iva esophageal squamous cell carcinoma confirmed by clinical pathological staging; 2. ≥18 years; 3. eastern cooperative oncology group performance status score (ecog ps) is 0 \~ 1 points; 4. expected survival time ≥ 6 months; 5. patients agree and have the ability to follow the planned study visits, laboratory tests and other research steps. exclusion criteria: 1. patients with other malignant tumors; 2. patient had undergone surgery before admission; 3. pregnant or lactating women; 4. patients with other serious diseases; 5. patients who could not understand the experiment content and could not cooperate with them and refused to sign the informed consent form; 6. patients with contraindications to radiotherapy and chemotherapy; 7. other researchers think it is not suitable.

Keywords: escc ctdna
continued efficacy and safety of apomorphine in patients with late-stage parkinsons disease

Conditions: Parkinson Disease

Summary: study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.


Eligibility criteria:
inclusion criteria: * adults of any age ≥ 18 * men and non-pregnant, non-lactating women * women of childbearing potential had a negative serum (beta hcg) pre-study pregnancy test prior to randomization * women of childbearing potential used an acceptable form of contraception * patients with a clinical diagnosis of idiopathic parkinson's disease, i.e., not induced by drugs or caused by other diseases; * patients classified as stage (ii-iv) of the hoehn and yahr scale for staging the severity of parkinson's disease * the patient must have been on an optimally maximized oral therapy regimen. optimized oral anti-parkinson medications must have included levodopa/carbidopa inhibitors, in either immediate or delayed release forms, plus at least one direct acting oral dopamine agonist for at least 30 days prior to randomization * patients must have been receiving apomorphine subcutaneous injections for rescue therapy for off events for at least three months * the minimum apomorphine baseline-dosing requirement was an average of at least 2 doses per day over the week prior to enrollment. * patients participating in protocol apo401, an open-label study primarily designed to collect safety data, were eligible for participation in this trial without termination of participation in apo401 exclusion criteria: * patients under medical therapy for clinically significant psychoses or dementia not related to ingestion of anti-parkinson medications. (patients with hallucinations or other central adverse reactions associated solely with anti-parkinson medications were not excluded.) * patients with a history of drug or alcohol dependency within one year prior to study enrollment * patients with unstable and clinically significant disease of cardiovascular (including orthostatic hypotension), hematologic (including coombs' positive hemolytic anemia), hepatic, renal, metabolic, respiratory, gastrointestinal or endocrinological systems or neoplasm within the three months before the start of the study. * patinets with a history of true allergy to morphine or its derivatives (including apomorphine), sulfur, sulfur containing medications, sulfites, sulfates, tigan(r)(trimethobenzamide). * patients treated with experimental agents (other than apomorphine intermittent subcutaneous injections) within 30 days before study entry. patients with participation in mylan-sponsored study apo202 were excluded from participation in this study. * patients whose apomorphine regimen was characterized by administration methods other than intermittent subcutaneous injection. * patients who could not or would not sign an informed consent form.
induced pluripotent stem cells for disease research

Conditions: Hirschsprung Disease

Summary: the aim of this study is to determine the contribution of genetic factors to the pathogenesis of diseases, including diseases such as parkinson's disease, hirschsprung's disease, and autism. patient-derived cellular models of diseases will be developed, which will require the collection of blood samples from patients and healthy individuals in order to generate induced pluripotent stem cells (ipscs) for the development of ipsc-derived human cell cultures. these human cellular models will be phenotyped using a variety of methods, including cellular, molecular, and biochemical assays. because these human cellular models will retain the genetic background from the patients and control subjects, this will allow us to determine the contribution of genetics to disease phenotypes. such disease-specific pluripotent stem cell lines will be invaluable tools for many basic and translational research applications, including pathophysiological studies in a developmental context, and innovation and screening of small molecule drugs capable of reversing the disease phenotype and potentially leading to a cure for a broad range of diseases, where appropriate in vitro or in vivo disease models do not exist.


Eligibility criteria:
inclusion criteria: * individuals with hirschsprung disease * any disease severity accepted * individuals with or without other health issues accepted * unaffected / healthy relatives of individuals with hirschsprung disease exclusion criteria: * individuals who are unwilling or unable to provide blood sample * individuals who are unwilling or unable to provide informed consent * individuals who are outside the age range permitted for our study will be excluded. our study will only perform blood draws from individuals ages 13 and above.

Keywords: hirschsprung disease
rosiglitazone in subjects with type 2 diabetes mellitus who are inadequately controlled on insulin

Conditions: Diabetes Mellitus, Type 2

Summary: this 24-week study will compare the effects of adding the drug rosiglitazone (2mg and 4mg) or placebo to insulin in patients with type 2 diabetes mellitus (non-insulin-dependent) who have not achieved their blood glucose goal using insulin alone. this study requires a total of seven visits during 28 weeks.


Eligibility criteria:
inclusion criteria: * have type ii diabetes mellitus (non-insulin-dependent). * females must be post-menopausal (\> 12 months without a menstrual period), surgically sterile, or must be using oral contraceptive, norplant, depo-provera, an iud, or a diaphragm with spermicide or condoms. females of childbearing potential must use acceptable contraceptive measures for at least one month prior to screening and for 30 days after completing the study. * must have been on insulin therapy alone continuously for at least 8 weeks prior to screening (minimum dose of 30 units per day). patients taking insulin in combination with a single oral antidiabetic agent may have their oral agent discontinued and their insulin dose optimized over an 8 week period prior to screening if they are considered good study candidates in all other respects. * hba1c \> 7.5% at pre-screen or at screen for subjects who discontinue their antidiabetic agent at pre-screening. * provide signed informed consent. exclusion criteria: * females who are lactating, pregnant, or planning to become pregnant. * use of any drug called a thiazolidinedione within 6 months prior to screening, or more than one oral antidiabetic agent (including combinations of agents such as glucovance) in combination with insulin in the 3 months prior to screening. * use of any investigational drug for blood glucose control within 3 months of screening regardless of the treatment regimen, or use of any other investigational agent within 30 days preceding study entry. * use of niacin (not including doses found in multivitamins) or oral corticosteroids within 3 months of screening. * patients with ongoing swelling due to fluid accumulation or history of such requiring treatment with a drug in the 12 months prior to screening. * patients with a documented history of significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to the drugs called thiazolidinediones or similar drugs, or with prior fluid related intolerability to thiazolidinediones. * presence of clinically significant kidney or liver disease. * anemia. * presence of unstable or severe angina or coronary insufficiency. * patients with ongoing chf (chronic heart failure) or history of chf. * recent history or suspicion of current drug abuse or alcohol abuse.

Keywords: type 2 diabetes mellitus thiazolidinediones insulin
a study evaluating the safety, tolerability, and pharmacodynamic effects of gly-200 in type 2 diabetic patients

Conditions: Type 2 Diabetes

Summary: this study is a phase 2, randomized, double-blind, placebo-controlled, single-center study in adult patients with type 2 diabetes. it will evaluate the safety and tolerability of oral gly-200. subjects will participate in a ≤ 18-day screening period followed by a metformin washout period of approximately 14 days, and an inpatient period of 16 days. approximately 48 subjects will be randomized to 1 of 3 active treatment groups or 1 of 3 placebo groups. dosing will occur for 14 days. a follow-up clinic visit will occur on day 21 \[end of study (eos)\] or early termination (et).


Eligibility criteria:
key inclusion criteria: * patients diagnosed with type 2 diabetes: hemoglobin a1c (hba1c)) ≥ 6.0 and ≤ 8.5% at screening * body mass index (bmi) ≥ 18 and ≤ 40 at screening key exclusion criteria: * treated with any prescription medication for the treatment of type 2 diabetes or weight loss other than metformin in the last 3 months prior to screening * use of any drug treatment that affects gastric ph * use of any drug treatment that affects gastrointestinal motility * fasting blood glucose \> 190 mg/dl * diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (gi) tract or active disease within 12 months prior to screening * history of any previous abdominal or intestinal surgery including endoscopic, open or laparoscopic thoracic or abdominal surgery, surgical resection of the stomach, small or large intestine * clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being

Keywords: type 2 diabetes diabetes mellitus, type 2 gly-200 glyscend, inc.
comparative study of different neoadjuvant therapies before radical hysterectomy in stage ib2-iia2 cervical cancer

Conditions: Cervical Cancer

Summary: for stage ib2-iia2 cervical cancer patients, neoadjuvant therapy followed by radical hysterectomy and pelvic lymphadenectomy is one of the managements. post-operative concurrent chemo-radiotherapy is necessary if the patients have high-risk factors, including positive surgical margin, parametrium and pelvic nodes. our previous retrospective study showed that combination of neoadjuvant chemotherapy and brachytherapy reduced the proportion of post-operative concurrent chemo-radiotherapy compared to neoadjuvant chemotherapy alone.

in the present study, the patients with stage ib2-iia2 cervical cancer will receive either neoadjuvant chemo/brachytherapy or neoadjuvant chemotherapy before radical hysterectomy and pelvic+/- para-aortic lymph node dissection. according to the surgical findings, post-operative chemo-radiotherapy will be performed.

Eligibility criteria:
inclusion criteria: * histology confirmed cervical cancer * clinical stage ib2 or iia2 (figo 2009) exclusion criteria: * patients who not suitable for surgery * personal history of pelvic radiotherapy

Keywords: neoadjuvant chemotherapy brachytherapy radiotherapy
the effect of adhesiolysis during elective abdominal surgery on per- and postoperative complication, quality of life and socioeconomic costs

Conditions: Tissue Adhesions

Summary: official title: lapad - a prospective study on the effect of adhesiolysis during elective laparotomy or laparoscopy on per- and postoperative complication, quality of life and socioeconomic costs background: with improved surgical technology and ageing of the population the number of reoperations in the abdomen dramatically increases. the risk for a repeat laparotomy or laparoscopy is a high as 30% in the first ten years after a laparotomy. in over 95% of reoperations adhesiolysis is required to gain access to the abdominal cavity and operation area. adhesiolysis significantly increases the risk for inadvertent organ damage, such as enterotomies, leading to higher morbidity, mortality and socioeconomic costs. purpose: to define the impact of adhesiolysis on per- and postoperative complications, quality of life and socioeconomic costs. design: prospective observational study. primary outcomes: * adhesiolysis time * inadvertent enterotomy * seromuscular injury * miscellaneous organ damage * serious adverse events of operation (anastomotic leakage, delayed diagnosed perforation, wound infection, abdominal infection, haemorrhage, pneumonia, urinary tract infection, abscess, fistula, sepsis, death) secondary outcomes: * hospital stay * intensive care admission * reinterventions * in-hospital costs * parenteral feeding * short term readmissions (30 days) * quality of life (gastro- intestinal tract complaints, short form- 36(sf-36), dasi (duke activity score index(dasi) ) estimated enrollment: 800 start study: 1 june 2008 inclusion completion date: 1 june 2010 estimated study completion date: 1 february 2011


Eligibility criteria:
inclusion criteria: * planned elective laparotomy or laparoscopy * mentally competent * 18 years or older exclusion criteria: * operation cancelled * bad quality of data

Keywords: tissue adhesions adhesiolysis inadvertent enterotomy prospective cohort study quality of life
impact of different contraceptives on the immune system of hiv infected women in zambia

Conditions: HIV; Contraception; HIV Infections

Summary: in this study, 66 hiv-infected women who desire contraception will be randomly assigned to use either an iud or depo provera, and will be followed for six months. the study is intended to help investigators understand potential mechanisms by which hormonal contraception may hasten hiv disease progression.

in this randomized controlled trial, 66 hiv-infected women who desire contraception will be assigned to one of two treatment groups: iud or depo provera. the study builds on findings from a previous study which examined the safety and acceptability of hormonal contraception and iud among hiv-infected women. secondary analyses from the previous study indicated that women who were assigned to the hormonal arm appeared to have faster disease progression based on death and decline in cd4+ count as compared to women assigned to the iud arm. with the current study, investigators seek to understand potential mechanisms for the effect of hormonal contraception on hastening hiv disease progression. enrolled women will be asked to use the assigned contraception method for a period of six months, and various indicators of disease progression will be collected at four follow-up visits after randomization.

Eligibility criteria:
inclusion criteria: * confirmed hiv status by local rapid test algorithm * willingness to be randomized to a contraceptive method and continue that method for at least 6 months. * intention to stay in the study area for at least 6 months exclusion criteria: * currently pregnant or pregnant within the prior 6 months * currently breastfeeding * documented liver disease * history of coagulation disorder * active tuberculosis * anemia, defined as hgb \<8gm/dl * age \< 16 years (the age of consent in zambia); * eligible for antiretroviral therapy based on zambian national guidelines (cd4+ \< 200, or who stage iv, or cd4+\< 350 and who stage iii) * currently using an iud or hormonal method of contraception, or have used a hormonal contraceptive in the past 6 months

Keywords: hiv/aids contraception birth control cd4+ viral load t-cell activation b-cell activation hormonal intrauterine device depo provera women iucd treatment naive
previous injury history and performance of male elite ice hockey players

Conditions: Wounds and Injuries; Sports Physical Therapy

Summary: background: in ice hockey, skating is a combination of speed, power, and balance. objective:the aim of this study is to examine the relationship between previous injury history and on-ice and off-ice performance of elite male ice hockey players. methods: this study was designed as prospective cross-sectional study. fifty elite men's ice hokey players included (n=50, mean age 23y 8mo, sd 5y 3mo). off-ice performance measures were 30 m sprint test, broad jump test, push-up test, hexagon agility test, plank test. the 2 on-ice tests were 30m on-ice sprint test and cornering "s" turn agility test.the athletes' history of injury were including previous injury site, type, number and the mechanism of injury. results: in push up test, there was a significant difference in those who had left hand and right knee injuries and, athletes who had dislocation were found to be statistically significant (p \<0.05). according to cornering s turn agility test results, athletes who had puck injury were found to be statistically significant (p \<0.05). in 30m sprint and hexagon agility test results, athletes who had overuse injury were found to be statistically significant (p \<0.05). there was a significant correlation between on-ice 30m sprint and cornering s turn agility tests with broad jump test and also with off-ice push-up and plank tests (p\<0.05). conclusions: as a result of the performance tests, push up test might be a distinctive test in determining the performance of the athletes after injury. also on-ice tests had a correlation with off-ice plank test which is the indicator of core muscle strength.

we believe that the current performance and performance deficiencies of the athletes determined and existing training programs will be arranged to eliminate performance deficiencies. we wanted to raise awareness about whether there is a general deficiency in ice hockey performance caused by past injuries and which exercises should be included in the training program in order to overcome performance deficiencies.

Eligibility criteria:
inclusion criteria: * being a member of turkish ice hockey federation, * to be subject to any of the licensed athletes who played in the super league team * to be over 18, * to be male. exclusion criteria: * being under the age of 18, * being a woman, * having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.

Keywords: hockey performance testing muscular strength and endurance wounds and injuries
phlebotomy and lifestyle and diet advices vs lifestyle and diet advices only in patients with dysmetabolic liversiderosis

Conditions: Liver Cirrhosis; Iron Overload

Summary: insulin resistance-associated hepatic iron overload (ir-hio), also defined as dysmetabolic iron overload syndrome or dysmetabolic liversiderosis, is a common cause or iron overload in france, mainly in middle-age patients with increased serum ferritin levels associated with normal serum transferrin saturation, and normal serum iron concentration in the absence of other known cause of increased serum ferritin levels. treatment includes a combination of dietary measures and physical activity to correct metabolic disorders. phlebotomies seem to be beneficial when serum ferritin level is high. this study aims at comparing the effect of iron depletion (by phlebotomy) plus lifestyle and diet advices versus lifestyle and diet advices alone on blood glucose level and insulin sensitivity in subjects with ir-hio in order to assess the benefits of phlebotomies on the reduction of risk of diabetes and cardiovascular associated complications.

non applicable

Eligibility criteria:
inclusion criteria: * age over 18 * signed written informed consent * ferritin ≥ 450 µg/l and ≤ 1500 µg/l * hepatic iron overload proved by mri or histological biochemical measurement (iron hepatic concentration ≥ 50 μmol/g) * at least one of the following criteria : * body mass index \> 25 kg/m² * systolic blood pressure ≥ 140mmhg or diastolic blood pressure ≥ 90 mmhg or antihypertensive treatment * abdominal obesity (waist measurement ≥ 94 cm for men and ≥ 80 cm for women) * fasting triglyceridemia ≥ 1.7 mmol/l or triglyceride-lowering treatment * fasting hdl cholesterol \< 1.03 mmol/l for men and \< 1.29 mmol/l for women or hdl cholesterol-elevating treatment * fasting blood glycemia ≥ 5.6 mmol/l exclusion criteria: * subjects deprived of their liberty by judicial or administrative decision * pregnant women * other causes of increased serum ferritin levels: * inflammatory syndrome (crp \>10 mg/l) or inflammatory, immune or malignant diseases * hyper-hemolysis * alcohol consumption more than 210 g for men and 140 g for women per week within the year before inclusion * haemochromatosis established by the c282y homozygous genotype * chronic hepatic cytolysis due to : viral infection (hbv, hcv), alcohol, hyperthyroid disease, celiac disease, drug or immune hepatitis * increased serum ferritin levels - cataract syndrome (familial cataract or personal history of cataract before 50 years of age) * low ceruloplasmin level * porphyria (cutaneous signs) * contraindication of phlebotomy * haemoglobin \<13 g/dl for men and \<12g/dl for women (threshold established by the french blood agency) * congestive heart failure or coronary heart disease * hepatic failure (tp\<60%), renal failure (gfr \<50ml/min) or respiratory insufficiency (chronic dyspnea) * poor venous system * fasting blood glycemia \> 7 mmol/l or type 1 or type 2 diabetes, treated or not * use of drugs known to have anti-steatotic effects : metformin, thiazolidinedione

Keywords: phlebotomy dysmetabolic liversiderosis hepatic iron overload